Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

Eli Lilly derives nearly two-thirds of its second-quarter revenue from Mounjaro, Zepbound and Foundayo, underscoring its heavy reliance on GLP-1 weight-loss treatments. The company agreed to acquire autoimmune and allergy-focused Merida Biosciences for up to $2.875 billion in cash, contingent on development milestones, as part of a broader acquisition strategy spanning mental health, sleep disorders and infectious disease. While these deals are not expected to materially affect near-term sales or earnings, they are intended to diversify Lilly ahead of rising GLP-1 competition and eventual patent expirations.

Analysis

The investable issue is not pipeline breadth but whether Lilly can redeploy GLP-1 cash flow at returns above its already demanding embedded-growth valuation. Early-stage bolt-ons typically create little near-term earnings accretion while introducing milestone obligations, integration costs, and clinical binary risk; the market should treat these transactions as capital-allocation evidence rather than a new revenue leg until asset-level trial design, probability of success, and commercial rights are disclosed. A growing deal cadence can also cap multiple expansion if investors infer management sees internal pipeline depth as insufficient.

Over the next 1-3 months, relative performance should be driven more by prescription share, supply normalization, payer access, and oral incretin data than by small acquisitions. NVO has the clearest upside torque if an oral format expands adherence and reduces distribution friction, while LLY remains more exposed to any evidence that efficacy superiority does not translate into durable net-price superiority. PFE is not yet a credible fundamental hedge to either leader: a weight-loss optionality narrative can move the stock, but commercialization timing and tolerability data remain the gating variables.

The contrarian point is that patent risk is structurally real but not the relevant discounting mechanism for the next several quarters. The nearer risk is category maturation: broader access can raise volumes while compressing realized price through formulary competition, making revenue growth look resilient but FCF conversion and gross-margin progression disappoint. Conversely, investors may be underestimating how much durable obesity-treatment demand can support multiple product formats, limiting the downside from incremental competition unless switching data show clinically meaningful differentiation.

Key Decisions for Investors

• Maintain a beta-neutral long NVO / short LLY relative-value position over 3-6 months, sized modestly: target a 10-15% narrowing of the relative valuation/performance gap if oral-incretin adoption or payer access improves. Exit if LLY demonstrates sustained prescription-share gains alongside stable net pricing, or if NVO oral data show tolerability/adherence weakness.
• Do not buy ATAI solely on strategic-takeover optics. Treat it as a transaction-monitoring alert until definitive consideration, closing conditions, and contingent-value terms are independently verified; small-cap deal spreads can be dominated by financing, shareholder approval, and regulatory risk rather than Lilly fundamentals.
• For LLY holders, use 3-6 month downside puts or put spreads around the next prescription/pricing update rather than reducing exposure solely on acquisition headlines. The key hedge trigger is a guidance revision tied to realized price, gross margin, or manufacturing costs—not a change in headline demand.
• Avoid using PFE as a direct short-term GLP-1 catch-up trade. Reassess only after pivotal efficacy, discontinuation, and manufacturing-scale data establish a commercially viable profile; until then, upside is narrative-driven and downside remains execution-heavy.